The antigenic anatomy of SARS-CoV-2 receptor binding domain

Abstract

Antibodies are crucial to immune protection against SARS-CoV-2, with some in emergency use as therapeutics. Here, we identify 377 human monoclonal antibodies (mAbs) recognizing the virus spike and focus mainly on 80 that bind the receptor binding domain (RBD). We devise a competition data-driven method to map RBD binding sites. We find that although antibody binding sites are widely dispersed, neutralizing antibody binding is focused, with nearly all highly inhibitory mAbs (IC 50 < 0.1 μg/mL) blocking receptor interaction, except for one that binds a unique epitope in the N-terminal domain. Many of these neutralizing mAbs use public V-genes and are close to germline. We dissect the structural basis of recognition for this large panel of antibodies through X-ray crystallography and cryoelectron microscopy of 19 Fab-antigen structures. We find novel binding modes for some potently inhibitory antibodies and demonstrate that strongly neutralizing mAbs protect, prophylactically or therapeutically, in animal models.

Cited by papers we hold 16

• A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies · 2023
  No notice
• Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants · 2022
  Not checked
• Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron · 2022
  Corrected
• Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models · 2022
  No notice
• BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection · 2022
  No notice
• Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants · 2022
  No notice
• SARS-CoV-2 Omicron variant: recent progress and future perspectives · 2022
  No notice
• Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines · 2022
  No notice
• Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models · 2022
  No notice
• Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera · 2021
  No notice
• Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera · 2021
  No notice
• Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants · 2021
  No notice
• Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies · 2021
  No notice
• Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice · 2021
  No notice
• Scientific rationale for developing potent RBD-based vaccines targeting COVID-19 · 2021
  No notice
• Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.